ASTRO 2022 | Real-world associations between PSA screening and metastatic prostate cancer incidence

Alex Bryant, MD, University of Michigan, Ann Arbor, MI, discusses the efficacy of PSA screening and whether it can help reduce metastatic prostate cancer (mPC) incidence. A recent real-world study analysed PSA screening rates and mPC incidence at 128 sites across the USA from 2005-2019. Sites with lower PSA screening rates were found to have higher rates of subsequent mPC. These results appear to support the use of PSA screening for reducing mPC incidence but this study only shows a correlation, not necessarily a causation. Future directions for this research include investigating mPC mortality and screening-related harms, such as false positives, biopsy complications, and over-diagnosis. This interview took place at the American Society for Radiation Oncology (ASTRO) 2022 Congress in San Antonio, Tx.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.